Global law firm White & Case LLP has advised Karo Pharma on the acquisition of Sylphar for €300 million (including contingent parts thereof) from private equity firm Vendis Capital and Robin List, Sylphar's founder.
Karo Pharma is a consumer healthcare company, which develops and markets branded consumer healthcare, OTC and Rx products in the drugstore, pharmacy, e-pharmacy and e-commerce channels. Karo Pharma is listed on Nasdaq Stockholm and is majority owned by EQT.
Belgium-based Sylphar develops and markets over-the-counter products such as Nutravita, Alpha Foods and Remescar, worldwide, mainly online, focusing on bringing innovative and consumer friendly products to the global market.
The White & Case team which advised on the transaction was led by partners Jan Jensen and Patrik Erblad (both Stockholm) and included partners Tilman Kuhn (Düsseldorf, Brussels), Johan Thiman and Oscar Liljeson (both Stockholm), local partner Thomas Glauden (Brussels), counsel Peter Svanqvist (Stockholm) and associates Andreas Lexhag, Victor Aberg, Gustaf Wiklund, Alexander Berlin-Jarhamn, Rebecka Tenenbaum and Zacharias Ngiam (all Stockholm), Philippe Hendrickx, Stefania Sacuiu and Louise Lundberg (all Brussels).
For more information please speak to your local media contact.